Investigating how a specific receptor in brain cells can protect against Alzheimer's disease.
Official title: The Neuroprotective Role of PPAR-delta in Microglia
Funded at University of California-Irvine · NIH-10936522 · Data updated 2026-11-12
This study is looking at how a specific protein in brain immune cells might help reduce inflammation and improve thinking skills in people with Alzheimer's disease, with the hope of finding new ways to treat this condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $53,974 |
| NIH project number | 5F30AG081084-02 |
| Project ID | NIH-10936522 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with mild-to-moderate Alzheimer's disease, particularly those with the APOE ε4 genetic risk factor.
✕Less likely to help
Patients with advanced Alzheimer's disease or those without the APOE ε4 risk factor may not benefit from this research.
What this research studies
This research focuses on the role of Peroxisome Proliferator-Activated Receptor delta (PPARd) in microglia, the immune cells of the brain, to understand how it may help protect against Alzheimer's disease (AD). The study will explore how activating PPARd can reduce inflammation and potentially improve cognitive function in models of AD. By examining the effects of PPARd activation on microglial cells, researchers aim to uncover new therapeutic strategies for treating AD. The findings could lead to better understanding and treatment options for patients suffering from this debilitating condition.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow down or prevent the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promising results with PPARd agonism in animal models of neurodegenerative diseases, indicating potential for success in human applications.
Where this research is happening
-
University of California-Irvine
Irvine, United States Active
Researchers
- Principal investigator: Deyell, Jacob Sahag — University of California-Irvine
- Study coordinator: Deyell, Jacob Sahag
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.